MedTrace Logo

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

NCT00959686 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2013-02-12

No results posted yet for this study

Summary

A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell lymphoma "BENTLY".

Conditions

Interventions

DRUG

Bendamustine

Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles

Sponsors & Collaborators

  • Mundipharma Pte Ltd.

    collaborator INDUSTRY

  • French Innovative Leukemia Organisation

    lead OTHER

Principal Investigators

  • Gandhi DAMAJ, MD MS · French Innovative Leukemia Organisation

  • Rémy GRESSIN, MD MS · French Innovative Leukemia Organisation

  • THierry LAMY, PD MS · French Innovative Leukemia Organisation

  • Olivier TOURNILHAC, PD MS · French Innovative Leukemia Organisation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-06-30
Completion
2013-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959686 on ClinicalTrials.gov